Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about RAS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
RAS is a gene implicated in neurodegeneration research. Key relationships include: interacts with, activates, associated with. Associated with AD, ADH, ALS. Connected to 1154 entities in the SciDEX knowledge graph.
| Gene Symbol | RAS |
| Full Name | Russian Academy of Sciences |
| Protein Type | National Academy of Sciences |
| Pathways | APOPTOSIS |
| GeneCards | RAS |
| Human Protein Atlas | RAS |
| Location | Moscow, Russia |
| Founded | 1724 |
| Website | https://www.ras.ru |
| Associated Diseases | AD, ADH, ALS, AMI, Aging |
| Known Drugs/Compounds | KRAS inhibitors, SEMAGLUTIDE, RAPAMYCIN, Lonafarnib, MNNG, angiotensin receptor blockers |
| Interactions | ROS, UBIQUITIN, DNM1L, CTSD, ATG, HIF1A |
| KG Connections | 2322 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
RAS["RAS"] -->|"regulates"| Ischemia["Ischemia"]
RAS["RAS"] -->|"activates"| Metabolic_Syndrome["Metabolic Syndrome"]
RAS["RAS"] -->|"interacts"| Alzheimer["Alzheimer"]
RAS["RAS"] -->|"interacts"| ALS["ALS"]
RAS["RAS"] -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
RAS["RAS"] -->|"interacts"| Dementia["Dementia"]
NF1["NF1"] -->|"regulates"| RAS["RAS"]
CAMP["CAMP"] -->|"activates"| RAS["RAS"]
MTOR["MTOR"] -->|"regulates"| RAS["RAS"]
MYC["MYC"] -->|"regulates"| RAS["RAS"]
style RAS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| Tumor | activates | disease | 1.00 |
| Cancer | associated_with | disease | 1.00 |
| Cancer | activates | disease | 1.00 |
| Apoptosis | activates | pathway | 1.00 |
| Autophagy | activates | pathway | 1.00 |
| CANCER | activates | gene | 1.00 |
| Carcinoma | activates | disease | 1.00 |
| Mapk | activates | pathway | 1.00 |
| CANCER | associated_with | gene | 1.00 |
| Als | activates | disease | 1.00 |
| Als | therapeutic_target | disease | 1.00 |
| AKT | activates | gene | 1.00 |
| Tumor | inhibits | disease | 1.00 |
| CANCER | therapeutic_target | gene | 1.00 |
| Tumor | therapeutic_target | disease | 1.00 |
| Cancer | therapeutic_target | disease | 1.00 |
| Receptor Tyrosine Kinase | activates | pathway | 1.00 |
| Als | inhibits | disease | 1.00 |
| GENES | inhibits | gene | 1.00 |
| GENES | activates | gene | 1.00 |
| Mapk | associated_with | pathway | 1.00 |
| Tumor | associated_with | disease | 0.95 |
| Als | associated_with | disease | 0.95 |
| Cancer | regulates | disease | 0.95 |
| Colorectal Cancer | activates | disease | 0.95 |
| Cancer | inhibits | disease | 0.95 |
| MAPK Pathway | activates | pathway | 0.95 |
| MAPK signaling pathway | upstream_of | pathway | 0.95 |
| cellular functions | regulates | process | 0.95 |
| cell proliferation | regulates | process | 0.95 |
| cancer | therapeutic_target | disease | 0.95 |
| colorectal cancer | associated_with | disease | 0.95 |
| KRAS inhibitors | therapeutic_target | drug | 0.95 |
| Mapk Pathway | activates | pathway | 0.95 |
| Pancreatic Ductal Adenocarcinoma | risk_factor_for | disease | 0.90 |
| gastric intestinal metaplasia | promotes | phenotype | 0.90 |
| cell transformation | promotes | process | 0.90 |
| Carcinogenesis | involved_in | process | 0.90 |
| neural stem cells | regulates | cell_type | 0.90 |
| AUTOPHAGY | activates | gene | 0.90 |
| Mtor | activates | pathway | 0.90 |
| EGF | activates | gene | 0.90 |
| CANCER | regulates | gene | 0.90 |
| CANCER | inhibits | gene | 0.90 |
| Erk Signaling | activates | pathway | 0.90 |
| Differentiation | activates | pathway | 0.90 |
| JAK | activates | gene | 0.90 |
| acquired resistance | promotes | phenotype | 0.88 |
| Inflammation | activates | disease | 0.85 |
| Aging | therapeutic_target | disease | 0.85 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOPTOSIS | activates | gene | 1.00 |
| PI3K | activates | gene | 1.00 |
| ERK | activates | gene | 1.00 |
| KRAS | activates | gene | 1.00 |
| RAPAMYCIN | activates | drug | 0.95 |
| metabolic syndrome | causes | disease | 0.90 |
| angiotensin receptor blockers | inhibits | drug | 0.90 |
| ATG | activates | gene | 0.90 |
| rapamycin | targets | drug | 0.90 |
| PI3K | therapeutic_target | gene | 0.90 |
| EGFR | activates | gene | 0.90 |
| MNNG | activates | drug | 0.85 |
| SPRED1 | inhibits | protein | 0.85 |
| NF1 | regulates | gene | 0.80 |
| SHOC2 | regulates | protein | 0.80 |
| Lonafarnib | inhibits | drug | 0.80 |
| RAB7A | activates | gene | 0.80 |
| AMPK | regulates | gene | 0.80 |
| BECN1 | regulates | gene | 0.80 |
| LAMP2 | regulates | gene | 0.80 |
| NATURAL PRODUCTS | regulates | compound | 0.80 |
| AUTOPHAGY | activates | gene | 0.80 |
| ERK | inhibits | gene | 0.80 |
| KRAS | therapeutic_target | gene | 0.80 |
| PI3K | inhibits | gene | 0.80 |
| HIF | activates | gene | 0.80 |
| CYTOKINES | activates | gene | 0.80 |
| ERK | therapeutic_target | gene | 0.80 |
| MAP1LC3B | activates | gene | 0.75 |
| ROS | activates | gene | 0.70 |
| STAT3 | activates | gene | 0.70 |
| TP53 | activates | gene | 0.70 |
| ERK | associated_with | gene | 0.70 |
| ERBB2 | activates | gene | 0.70 |
| AMPK | activates | gene | 0.70 |
| CREB | activates | gene | 0.70 |
| ERK | contributes_to | gene | 0.70 |
| P53 | inhibits | gene | 0.70 |
| PTEN | activates | gene | 0.70 |
| NF-ΚB | activates | gene | 0.70 |
| BAX | inhibits | gene | 0.70 |
| VEGF | therapeutic_target | gene | 0.70 |
| BRAF | activates | gene | 0.70 |
| KRAS | associated_with | gene | 0.70 |
| PKC | activates | gene | 0.70 |
| NEURODEGENERATION | activates | gene | 0.70 |
| FERROPTOSIS | activates | gene | 0.70 |
| PI3K | expressed_in | gene | 0.70 |
| APOPTOSIS | inhibits | gene | 0.70 |
| MTORC1 | activates | gene | 0.70 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neuropharmacology | 2026-04-11 | 0 hypotheses
neuroinflammation | 2026-04-08 | 0 hypotheses
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in [PMID:41651379] | Huang X, Sun YY, Qin YR, Chen H, Pan TT | J Control Release | 2026 | 0 |
| Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyro [PMID:41679437] | Chen C, Tan S, Zhu X, Song Z, Xing Y et | J Control Release | 2026 | 0 |
| Covalent Bond Locking in Semiconducting Oligomers Boosts Ultrabright NIR-II Lumi [PMID:41757652] | Li X, Gan H, Zhang C, Gao Y, Zhang J et | Angew Chem Int Ed Engl | 2026 | 0 |
| Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593] | Yoshida K, Saito N, Takahashi R, Ando S, | J Alzheimers Dis | 2026 | 0 |
| UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylati [PMID:41930933] | Ding SK | Immunol Invest | 2026 | 0 |